Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis
- 1 January 2000
- journal article
- research article
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 51 (1) , 1-7
- https://doi.org/10.1016/s0016-5107(00)70377-4
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trialGastrointestinal Endoscopy, 1999
- Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized studyGastrointestinal Endoscopy, 1998
- Gabexate for the Prevention of Pancreatic Damage Related to Endoscopic Retrograde CholangiopancreatographyNew England Journal of Medicine, 1996
- Complications of Endoscopic Biliary SphincterotomyNew England Journal of Medicine, 1996
- The Use of a Long-Acting Somatostatin Analogue (Octreotide) for Prophylaxis of Acute Pancreatitis after Endoscopic SphincterotomyEndoscopy, 1994
- Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?Gut, 1992
- Endoscopic sphincterotomy complications and their management: an attempt at consensusGastrointestinal Endoscopy, 1991
- ERCP- and Endoscopic Sphincterotomy-Induced PancreatitisPancreas, 1991
- The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatographyGastrointestinal Endoscopy, 1991
- Prevention of Pancreatic Reactions by Bolus Somatostatin Administration in Patients Undergoing Endoscopic Retrograde Cholangio-Pancreatography and Endoscopic SphincterotomyHormone Research, 1988